Japanese biopharmaceutical company focused on developing treatments for liver diseases
Japanese biopharmaceutical company focused on developing treatments for liver diseases. It holds development and commercialization rights in Japan and South Korea for lanifibranor, a pan-PPAR agonist being developed for MASH/NASH; the drug completed a Phase I trial in Japan in 2025, while Phase III trials are underway in Europe and the United States.